Biotech iQ
@biotechiq.bsky.social
Tech entrepreneur, science nerd, and biotech investor for over 20 years. I don't offer financial advice, only my own opinions.
https://www.biotechiq.net/about-biotech-iq/
https://www.biotechiq.net/about-biotech-iq/
$EOLS (L) pre-announced $79.0M unaudited 2024Q4 revenue, above my and market estimates as revenue growth rebounded in Q4. The company has several tailwinds heading into 2025 including an earlier-than-expected launch of Evolysse now expected in 2025 Q2. Updated Biotech iQ Q4 Scorecard:
#biotech
#biotech
January 25, 2025 at 10:27 PM
$EOLS (L) pre-announced $79.0M unaudited 2024Q4 revenue, above my and market estimates as revenue growth rebounded in Q4. The company has several tailwinds heading into 2025 including an earlier-than-expected launch of Evolysse now expected in 2025 Q2. Updated Biotech iQ Q4 Scorecard:
#biotech
#biotech
$AUTL (L) Quick comparison of Aucatzyl vs. Blincyto vs. Tecartus:
January 25, 2025 at 10:02 PM
$AUTL (L) Quick comparison of Aucatzyl vs. Blincyto vs. Tecartus:
$AUTL (L) The recent approval of Aucatzyl transforms AUTL from a clinical to a commercial company. Aucatzyl has demonstrated best-in-class data for the treatment of R/R adult B-ALL and is the only CAR-T therapy without a REMS requirement due to obe-cel’s favorable safety profile.
January 25, 2025 at 10:01 PM
$AUTL (L) The recent approval of Aucatzyl transforms AUTL from a clinical to a commercial company. Aucatzyl has demonstrated best-in-class data for the treatment of R/R adult B-ALL and is the only CAR-T therapy without a REMS requirement due to obe-cel’s favorable safety profile.
$MIST (L) With its PDUFA target date for CARDAMYST coming up in March, please feel free to check out my article on Milestone Therapeutics (no paywall).
www.biotechiq.net/free-biq-rev...
www.biotechiq.net/free-biq-rev...
#Free BiQ: Revisiting Milestone Therapeutics (MIST)
Introduction
With the PDUFA target date for Etripamil, known by the trade name CARDAMYST, for treating PSVT on March 27, 2025, I thought this would be a good time to revisit the thesis for Milestone ...
www.biotechiq.net
January 25, 2025 at 9:52 PM
$MIST (L) With its PDUFA target date for CARDAMYST coming up in March, please feel free to check out my article on Milestone Therapeutics (no paywall).
www.biotechiq.net/free-biq-rev...
www.biotechiq.net/free-biq-rev...